Cabazitaxel for the treatment of prostate cancer

Bibliography

• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;12:765-81
   Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• Cancerline UK. Available from: http://www.cancerlineuk.net/prostatecancer [Last accessed May 2010]
   Google Scholar
• American Cancer Society. Prostate cancer statistics. Available from: http://www.cancer.org [Last accessed May 2010]
   Google Scholar
• American Society of Clinical Oncology. Prostate cancer statistics. Available from: http://www.cancer.net/prostate [Last accessed May 2010]
   Google Scholar
• Tannock IF, Osoba D, Stockler MR, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996;14:1756-64
   PubMed Web of Science ®Google Scholar
• Gelfand VI, Bershadsky AD. Microtubule dynamics: mechanism, regulation, and function. Annu Rev Cell Biol 1991;7:93-116
   PubMedGoogle Scholar
• Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994;344:1267-72
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Tolcher AW. Antimicrotubule agents. In: DeVita V, Hellman S, Rosenberg SA, editors, Cancer: principle and practice of oncology. Lippincott, Williams & Wilkins, Philadelphia, PA; 2001. p. 431-51
   Google Scholar
• Yoshino T, Shiina H, Urakami S, Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 2006;12:6116-24
   PubMed Web of Science ®Google Scholar
• Savarese DM, Halabi S, Hars V, Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001;19:2509-16
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, Soban F, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: update survival in the TAX 327 study. J Clin Oncol 2008;26:242-5
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, de Wit R, ; TAX 327 Investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19:1749-53
   PubMed Web of Science ®Google Scholar
• Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61
   PubMed Web of Science ®Google Scholar
• So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005;23:1-9
   PubMed Web of Science ®Google Scholar
• Greenberger LM, Lothstein L, Williams SS, Horwitz SB. Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci USA 1988;85:3762-6
   PubMed Web of Science ®Google Scholar
• Hari M, Wang Y, Veeraraghavan S, Cabral F. Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol Cancer Ther 2003;2:597-605
   PubMed Web of Science ®Google Scholar
• Ranganathan S, Dexter DW, Benetatos CA, Increase of B(III) and B(Iva)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 1996;56:2584-9
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65
   PubMed Web of Science ®Google Scholar
• Kavallaris M, Tait AS, Walsh BJ, Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 2001;61:5803-9
   PubMed Web of Science ®Google Scholar
• Zhang CC, Yang JM, White E, The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 1998;16:1617-24
   PubMed Web of Science ®Google Scholar
• Bissery MC, Bouchard H, Riou JF, Preclinical evaluation of TXD258, a new taxoid. Proc Am Assoc Cancer Res 2000;14: abstract 1364
   Google Scholar
• Aller AW, Kraus LA, Bissery MC. In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines. Proc Am Assoc Cancer Res 2000;41: abstract 1923
   Google Scholar
• Vrignaud P, Lejeune P, Chaplin D, In vivo efficacy of TXD258, a new taxoid, against human tumor xenografts. Proc Am Assoc Cancer Res 2000;41: abstract 1365
   Google Scholar
• Bissery MC, Vrignaud P, Riou JF, In vivo isolation and characterization of a docetaxel resistant B16 melanoma. Proc Am Assoc Cancer Res 1995;36: abstract 1882
   Google Scholar
• Dykes DJ, Sarsat JP, Bissery MC. Efficacy evaluation of TXD258, a taxoid compound against orthotopic and subcutaneous glioblastomas. Proc Am Assoc Cancer Res 2000;41: abstract 1916
   Google Scholar
• Bissery MC. Preclinical evaluation of new taxoids. Curr Pharm Des 2001;7:1251-7
   PubMed Web of Science ®Google Scholar
• Mita AC, Denis LJ, Rowinsky EK, Phase I and pharmacokinetic study of XRP6258 (RPR116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15:723-30
   PubMed Web of Science ®Google Scholar
• Pivot X, Koralewski P, Hidalgo JL, A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008;19:1547-52
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, Prednisone plus cabaitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54
   PubMed Web of Science ®Google Scholar
• Scher HI, Halabi S, Tannock I, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working group. J Clin Oncol 2008;26:1148-59
   PubMed Web of Science ®Google Scholar
• de Bono JS, Scher HI, Montgomery RB, Circulating tumor cells predict survival benefit from treatment in metastatic castration resistant prostate cancer. Clin Cancer Res 2008;14:6302-9
   PubMed Web of Science ®Google Scholar
• Kramer G, Schwarz S, Hagg M, Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 2006;94:1592-8
   PubMed Web of Science ®Google Scholar
• de Bono J, Logothetis CJ, Fizazi K, Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel-based chemotherapy: results of COU-AA-301, a randomized, double-blind, placebo-controlled phase III study. Presented at the 35th European Society for Medical Oncology Congress; 11 October 2010. Ann Oncol 2010;21(suppl):viii3
   Google Scholar
• Fitzpatrick JM, Anderson J, Sternberg CN, Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. Crit Rev Oncol Hematol 2008;68:S9-22
   Web of Science ®Google Scholar